BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab. Adv Ther 2016;33:1947-63. [PMID: 27664107 DOI: 10.1007/s12325-016-0406-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gil-candel M, Gascón-cánovas JJ, Urbieta-sanz E, Rentero-redondo L, Onteniente-candela M, Iniesta-navalón C. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease. Int J Clin Pharm 2020;42:500-7. [DOI: 10.1007/s11096-020-00978-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]
3 Morikubo H, Kobayashi T, Fukuda T, Nagahama T, Hisamatsu T, Hibi T. Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database. PLoS One 2021;16:e0258537. [PMID: 34644342 DOI: 10.1371/journal.pone.0258537] [Reference Citation Analysis]
4 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
5 Durand JK, Baldwin AS. Targeting IKK and NF-κB for Therapy. Adv Protein Chem Struct Biol 2017;107:77-115. [PMID: 28215229 DOI: 10.1016/bs.apcsb.2016.11.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
6 Magro F, Sottomayor C, Alves C, Santiago M, Ministro P, Lago P, Correia L, Gonçalves R, Carvalho D, Portela F, Dias CC, Dignass A, Danese S, Peyrin-biroulet L, Estevinho MM, Leão Moreira P. Composite outcomes in observational studies of Crohn’s disease: a systematic review and meta-analysis. Therap Adv Gastroenterol 2022;15:175628482210927. [DOI: 10.1177/17562848221092754] [Reference Citation Analysis]
7 Masui S, Yonezawa A, Momo K, Nakagawa S, Itohara K, Imai S, Nakagawa T, Matsubara K. Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study. Biol Pharm Bull 2022;45:323-32. [PMID: 35228398 DOI: 10.1248/bpb.b21-00906] [Reference Citation Analysis]
8 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
9 Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. J Gastroenterol Hepatol 2020;35:225-32. [PMID: 31397010 DOI: 10.1111/jgh.14825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chen Y, Li H, Feng Q, Shen J. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients. Front Pharmacol 2021;12:654985. [PMID: 33986682 DOI: 10.3389/fphar.2021.654985] [Reference Citation Analysis]
11 Uda A, Kuwabara H, Shimizu S, Iwakiri R, Fushimi K. Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease. JGH Open 2020;4:532-40. [PMID: 32514466 DOI: 10.1002/jgh3.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]